MDMA THERAPY

Psilocybin therapy has been attracting significant attention in recent years, particularly as a potential addition to existing forms of treatment for depression. A new randomized, placebo-controlled trial in JAMA Network Open It focuses specifically on people with recurring depressive symptoms and investigates what happens after a single supervised dose of psilocybin. The results show a rapid difference in the first few weeks, but also provide clear reasons to be cautious about drawing conclusions regarding the long term.

In this article, we explain in an accessible way exactly what the study investigated, what the results mean, what limitations exist, and what this can say about therapy with psychedelics in general. In doing so, we explicitly distinguish between what has been found in scientific research and what can or cannot be deduced from it for clinical practice.

What exactly did this JAMA study investigate?

The study was conducted in Sweden at the Northern Stockholm Psychiatric Clinic and the Karolinska Institutet. A total of 35 participants with recurrent depressive symptoms, in a moderate to severe depressive episode, took part. It was therefore a relatively small study, but one with a design that is stronger than many previous exploratory studies.

Participants were randomly divided into two groups:

1) 17 participants received one dose of 25 mg psilocybin.

2) 18 participants received 100 mg niacin (vitamin B3) as an active placebo.

Important detail: both groups received psychotherapeutic support surrounding the session. The trajectory consisted of one preparatory session, one dosing day, and three integration sessions within 17 days. During the dosing day, participants were encouraged to turn inward, using music, an eye mask, and guidance from psychologists, among other things. In doing so, the study investigates not “psilocybin alone,” but psilocybin in a structured, guided context that can be viewed as a form of therapy with support.

The most important outcome: faster difference on day 8

The primary outcome measure was the change in depressive symptoms on day 8, measured using the MADRS score (a widely used clinical scale). At that time point, the MADRS score in the psilocybin group decreased by an average of 7.27 points more strongly than in the niacin group. This difference was statistically significant.

This is relevant because many standard interventions for depressive symptoms do not always produce a quickly noticeable effect, certainly not within one week. At the same time, “statistically significant” is not the same as “noticeable to everyone” or “lasting”. It indicates that the average difference between groups is likely not due to chance within this sample, but it reveals less about individual variation and sustainability.

How long did the effect last in this study?

The researchers did not only look at day 8. On day 15 and day 42, the difference between psilocybin and niacin remained significant as well. On day 15, the average difference was 11.03 points in favor of psilocybin. On day 42, this difference was 8.33 points.

In plain language: in the first six weeks after the session, the psilocybin group scored clearly better on the clinical depression scale than the placebo group, within this study design and among these selected participants.

The study also included long-term follow-up. On day 365, i.e., after one year, the difference between the groups was no longer statistically significant. This does not automatically mean that there was “no effect,” but rather that the difference between the groups at the end of the year was not convincing enough to present it as a reliable group difference. Therefore, for claims regarding sustained efficacy after a single dose, this study actually serves as a data point that puts things into perspective.

Self-report: improvement already from day 2, but with a caveat

In addition to the assessment by researchers, participants also completed self-assessment questionnaires (MADRS-S). On these, the difference between psilocybin and niacin was visible as early as day 2, and in the main analysis, this persisted until day 102.

That is interesting because it suggests that participants could experience change quickly. At the same time, there is an important methodological point here: in psychedelic research, it is often quickly clear to participants whether they have received the active substance. This can reinforce expectations and influence self-reporting. Self-reporting is valuable, but in this type of research, it is particularly sensitive to expectation effects.

Remission: notable difference on day 42, not convincing after a year

An outcome that attracts significant attention is remission (achieving a score below a certain threshold, meaning that according to the scale, a person no longer meets depression criteria). On day 42, 52.9% met remission criteria in the psilocybin group, compared to 5.9% in the niacin group. In terms of numbers, this involved 9 out of 17 participants versus 1 participant in the placebo group (among the assessed participants).

However, the long-term nuance is important here as well. On day 365, the difference was no longer statistically significant: 52,9% remission in the psilocybin group versus 41,2% in the niacin group. This could mean several things, for example, that the effect after a single session diminishes in some individuals, or that people in both groups improve in other ways over the course of the year. The study shows that a single session might make a quick difference, but not that this remains clearly better than placebo for a full year in everyone.

Why therapy and context are not “side issues” here

This study was not set up as a “take a substance and you’re done.” There was preparation, guidance on the day itself, and integration. In the practice of psychedelic research, it is actually believed that the combination of experience and integration is important for how someone gives meaning to what happens and how insights are translated into behavior, coping, and choices in daily life.

What you can deduce from this study, therefore, is that the intervention studied is a package: a dose of psilocybin plus psychotherapeutic support in a controlled setting. What you cannot deduce from it is how psilocybin would work “on its own” without screening, guidance, and integration, or how it would work for people with profiles different from the selected participants.

Safety: usually mild, but not without risks

Most side effects were temporary and mild to moderate. In the psilocybin group, headache, anxiety, hallucinations, agitation, increased blood pressure, and tingling were reported, among others. No serious side effects were reported that were assessed as directly related to psilocybin.

However, the study contains an important safety signal: two participants in the psilocybin group reported severe and persistent anxiety requiring medical attention. This is a relevant reminder for harm reduction: even in a controlled research setting with professional supervision, a session can be psychologically demanding and trigger symptoms that do not “just go away on their own.”.

Therefore, it is generally wise not to frame psychedelic therapy as mild, risk-free, or predictable. Research is precisely about identifying who might benefit, who is at increased risk, and what support is needed.

A major limitation: blinding hardly worked.

One of the main limitations of this study is that the blinding did not hold up well. At the end of the study, 94.1% of the participants in the psilocybin group correctly guessed that they had received psilocybin. In the niacin group, as many as 100% correctly guessed that they had received niacin.

Raters were also able to estimate relatively often which group someone belonged to. This is not just a technical detail: if participants and researchers largely know what has been administered, expectations and interpretations can unintentionally explain part of the difference. The researchers therefore conclude that niacin as an active placebo was insufficient to maintain true blinding.

This is a recurring problem in psychedelic research and one of the reasons why various research groups are seeking better comparison conditions and methods.

For whom do these results apply and for whom do they not?

The study had strict exclusion criteria. Individuals with prior psychedelic use, psychotic or bipolar disorders, a first-degree relative with a psychotic disorder, current substance use disorder, pregnancy, ongoing antidepressant treatment, ongoing psychotherapy, or suicidality were excluded.

This means that the results are not readily applicable to everyone with depressive symptoms, and certainly not to people with more complex issues or acute risks. This is not unique to this study, but it is important to note, because public discussions about psychedelics sometimes generalize more quickly than the data allow.

What does this say about psilocybin therapy in practice?

This JAMA study supports the idea that psilocybin, with guidance during the first weeks to months, can make a difference in depression scores in a selected group with recurrent depressive symptoms. At the same time, the follow-up shows that the group difference does not remain convincing after one year, and that larger studies are needed to answer questions regarding sustainability, repeated dosing, and maintenance strategies.

Moreover, in the Netherlands and many other countries, psychedelic sessions, such as those in research, are not readily available as regular therapy. Currently, MDMA sessions can only be discussed and approached within scientific research or in clinical practice via harm reduction. For psilocybin, the situation differs depending on the context and form, but here too, it is important to maintain a clear distinction between research, care, and counseling practice.

Those who wish to delve deeper into the research findings can read the source article via this summary of the JAMA study on psilocybin for depressive symptoms.

If you are exploring guided sessions in general, it is advisable to critically examine screening, preparation, integration, the experience of facilitators, and harm-reduction agreements such as dosage, set and setting, emergency plan, and aftercare. If you would like to discuss this or register for a session request in a harm-reduction context, you can visit the page. sign up for an MDMA session.

Conclusion

The JAMA study on recurrent depressive symptoms shows that a single guided dose of psilocybin showed statistically significant improvements compared to an active placebo in the first weeks and up to approximately six weeks, with signs of rapid change. At the same time, there are clear limitations, such as inadequate blinding, a small group of participants, and a long-term effect that no longer differs convincingly after one year. The outcomes are therefore primarily a strong indication of short-term potential, not an endpoint. Further, larger studies remain necessary to better understand safety, sustainability, and optimal forms of therapy.